Class Action Alleges GoodRx Secretly Shares Prescription, Treatment Data with Facebook, Google [UPDATE]
Last Updated on January 27, 2026
Doe v. GoodRx Holdings, Inc. et al.
Filed: February 2, 2023 ◆§ 3:23-cv-00501
A class action alleges GoodRx has secretly shared consumer medical information with Google, Meta, Criteo and other major social media and advertising companies.
January 27, 2026 — Judge Denies $32M Settlement In Class Action Lawsuit Against GoodRx, Criteo
A $32 million settlement in the class action lawsuit described on this page was denied preliminary approval from the court on January 16, 2026.
This was the second time that California federal judge Araceli Martinez-Olguin denied a motion for preliminary approval of the class action settlement with GoodRx, as a $25 million settlement was proposed by the parties in November of 2024 to resolve allegations that GoodRx unlawfully tracked and shared site visitors’ browsing activity with third parties.
According to the order, Judge Martinez-Olguin outlined that the main problem with the $32 million settlement was the same reason the $25 million settlement was rejected the year prior—i.e., the plaintiffs had failed to provide a claim-by-claim analysis outlining the amount class members would recover if the plaintiffs prevailed on all their claims, and how they justified the discount from the potential class recovery.
“Plaintiffs’ failure to provide a claim-by-claim analysis leaves the Court unable to assess the fairness and adequacy of the settlement,” the judge wrote.
With regard to the broad release of claims required of each class member, Judge Martinez-Olguin stipulated that the release’s scope felt “insufficiently justified” considering that, according to the estimations of the plaintiffs’ counsel, each class member’s payout might only be around $10 with a 3- to 10-percent claims rate.
The rejection similarly came out of the court’s belief that the plaintiffs continued to fail to identify any discovery they had conducted to confirm the strength of their claims.
Don’t miss out on class action settlement news like this. Sign up for ClassAction.org’s free weekly newsletter.
A proposed class action alleges telehealth and prescription drug coupon provider GoodRx has secretly shared detailed consumer medical information with Google, Meta, Criteo and other major social media and advertising companies.
Want to stay in the loop on class actions that matter to you? Sign up for ClassAction.org’s free weekly newsletter here.
The 51-page GoodRx privacy lawsuit was filed a day after the company was barred via enforcement action by the Federal Trade Commission (FTC) from sharing consumers' sensitive health information for advertising purposes. Under the proposed order, GoodRx will pay a $1.5 million civil penalty, marking the first instance of the FTC taking an enforcement action over the sharing of user health data with third parties for advertising.
The lawsuit against GoodRx says that although the company affirms that it maintains the same medical data-protection guidelines as any other health entity, the company has “knowingly and intentionally” intercepted its users’ identifying prescription and treatment information and shared it with “at least a dozen” third parties for targeted advertising purposes.
According to the suit, GoodRx’s handling and disclosure of users’ medical data without consent and contrary to its privacy-policy assurances amounts to “an extreme invasion of … privacy” in violation of federal and state law.
“Given the nature of this information shared through the GoodRx Platform and GoodRx’s representations, Plaintiff and Class members believed their personal information, including health information relating to their medical conditions, symptoms, and prescriptions, would not be shared or disclosed,” the suit attests.
GoodRx is reportedly the most-downloaded medical app in the Apple and Google app stores, boasting roughly 20 million users per month, the case shares. The defendant’s service purports to allow consumers to save money on prescription drugs by gathering current prices and discounts and offering coupons they can present at a pharmacy when picking up a medication, the suit relays.
Moreover, GoodRx offers telehealth services under its HeyDoctor and GoodRx Care brands, the lawsuit says. To access any of GoodRx’s services, a consumer must provide detailed personally identifiable information, as well as select the type of treatment they’re looking to receive.
The lawsuit alleges GoodRx knowingly and intentionally loaded its platforms up with “a host of tracking technology,” including software development kits and tracking pixels developed by defendants Meta Platforms, Google and Criteo, for “marketing, advertising and analytics purposes” without disclosure to users. These tools exist for the express purpose of collecting data from users, the filing says.
“Defendant GoodRx monetized and used the data collected from GoodRx users to serve personalized advertisements,” the suit summarizes.
The lawsuit looks to cover all persons in the United States who used GoodRx and whose communications and/or data were shared with third parties, including Meta, Google and Criteo.
Get class action lawsuit news sent to your inbox – sign up for ClassAction.org’s free weekly newsletter here.
Video Game Addiction Lawsuits
If your child suffers from video game addiction — including Fortnite addiction or Roblox addiction — you may be able to take legal action. Gamers 18 to 22 may also qualify.
Learn more:Video Game Addiction Lawsuit
Depo-Provera Lawsuits
Anyone who received Depo-Provera or Depo-Provera SubQ injections and has been diagnosed with meningioma, a type of brain tumor, may be able to take legal action.
Read more: Depo-Provera Lawsuit
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.